The emerging role of checkpoint inhibitors for rare genitourinary cancers

Nature Reviews Urology, Published online: 11 January 2021; doi:10.1038/s41585-021-00426-8Rare genitourinary cancers have historically been challenging to treat given the scarcity in incidence, inadequacy of data on treatment and lack of general consensus to guide routine therapy. A phase II multicentre trial shows efficacy of nivolumab and ipilimumab in several cohorts of patients with rare genitourinary cancers.

Source: Nature Reviews Urology - January 11, 2021 Category: Urology & Nephrology Authors: Jeanny B. Aragon-Ching Source Type: research